巴瑞替尼单药或联合甲氨蝶呤对比依那西普治疗类风湿关节炎超声滑膜炎反应的随机国际多中心试验
主要终点为第12周双侧腕关节和掌指关节GLOESS变化,结果显示巴瑞替尼两组相对于依那西普联合甲氨蝶呤均达到非劣效。
要点
- 巴瑞替尼单药或联合甲氨蝶呤在第12周GLOESS变化上非劣于依那西普联合甲氨蝶呤。
- 金属蛋白酶-3浓度变化与所有超声评分变化显著相关。
核心结论
- 巴瑞替尼单药或联合甲氨蝶呤对超声评估滑膜炎的改善非劣于依那西普联合甲氨蝶呤。
主要发现
- 金属蛋白酶-3浓度变化与所有超声评分变化显著相关。
关键数值与推荐
- 主要终点为第12周双侧腕关节和掌指关节GLOESS变化,非劣效界值定义为依那西普联合甲氨蝶呤组变化的80%。
- 超声滑膜炎在B模式、多普勒模式及两者联合模式下按0至3分评分。
临床怎么用
- 对于甲氨蝶呤反应不佳的活动性类风湿关节炎患者,巴瑞替尼单药或联合甲氨蝶呤可作为与依那西普联合甲氨蝶呤相当的超声滑膜炎改善选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The primary objective of this randomised, active-controlled, international, multicentre, phase IV clinical trial was to demonstrate noninferiority of the response of ultrasound-assessed synovitis to baricitinib treatment, alone and in combination with methotrexate (MTX), compared with etanercept with MTX in rheumatoid arthritis (RA). METHODS: Adult patients with active RA and inadequate response to MTX were randomised into 3 parallel treatment groups: baricitinib monotherapy, baricitinib plus MTX, and etanercept plus MTX. The patients underwent clinical, ultrasound, and laboratory assessments at baseline, 4, 12, and 24 weeks. Ultrasound synovitis was scored 0 to 3 in B-mode, Doppler mode, and a combination of both modes. The primary endpoint was the change in the Global European Alliance of Associations for Rheumatology-Outcome Measures in Rheumatology Synovitis Score (GLOESS) for bilateral wrist and metacarpophalangeal joints at week 12. Noninferiority was stated if the changes in the baricitinib groups were above the lower limit of the noninferiority range, defined as 80% of changes observed in the etanercept plus MTX group. Changes in serum concentrations of different mediators were analysed at 24 weeks. RESULTS: One hundred fifty patients (109 women and 41 men) were randomised. All clinical and ultrasound variables showed significant improvement starting from week 4 across the 3 treatment arms (P < .050). Noninferiority of baricitinib (monotherapy and plus MTX) was confirmed against etanercept with MTX for GLOESS at week 12 (P < .050). Changes in metalloprotease-3 concentration significantly correlated with changes in all ultrasound scores. CONCLUSIONS: The response of ultrasound-assessed synovitis to baricitinib, alone or in combination with MTX, was noninferior to that of etanercept with MTX.
引用
- Naredo E, Olivas-Vergara O, Borges PE, et al. Response of ultrasound-assessed synovitis to baricitinib, in monotherapy and combined with methotrexate, compared with etanercept in rheumatoid arthritis: a randomised, international, multicentre trial. Ann Rheum Dis. 2026. PMID: 42025496. doi:10.1016/j.ard.2026.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。